Analyst Ratings January 27, 2026

Cantor Fitzgerald Sticks With Overweight on W.R. Berkley After Q4 2025 Results

Analyst holds $76 target as insurer posts steady underwriting margins, modest EPS miss and strong revenue beat

By Sofia Navarro WRB
Cantor Fitzgerald Sticks With Overweight on W.R. Berkley After Q4 2025 Results
WRB

Cantor Fitzgerald reiterated an Overweight rating and a $76.00 price target on W.R. Berkley following the insurer's fourth-quarter 2025 results. While Q4 diluted EPS of $1.13 was a hair below the firm's $1.14 estimate, Cantor Fitzgerald described the result as "effectively in-line overall." The company reported stronger-than-expected revenue and retains attractive valuation metrics, though other brokers trimmed price targets and maintained neutral ratings.

Key Points

  • Cantor Fitzgerald reiterated an Overweight rating and a $76 price target on W.R. Berkley after its Q4 2025 results; the stock trades at $66.88 according to InvestingPro data, implying upside to the target.
  • W.R. Berkley reported Q4 diluted EPS of $1.13, marginally below Cantor Fitzgerald's $1.14 estimate and described as "effectively in-line overall." The company delivered a revenue beat at $3.72 billion versus a $3.19 billion expectation.
  • Company fundamentals cited include a Piotroski Score of 9, gross profit margin of 43.85%, return on equity of 21%, a beta of 0.39, a 2.78% dividend yield with three consecutive annual raises, a P/E of 14.01 and a PEG of 0.6.

Cantor Fitzgerald has reaffirmed an Overweight recommendation on W.R. Berkley (NYSE:WRB) and kept its $76.00 price target after the company released fourth-quarter 2025 financial results. The stock is trading at $66.88 according to InvestingPro data, implying potential upside to the Cantor Fitzgerald target.

The insurer reported diluted earnings per share of $1.13 for the fourth quarter, narrowly missing Cantor Fitzgerald's $1.14 projection. The firm characterized that shortfall as "effectively in-line overall." On a trailing-twelve-month basis, diluted EPS stands at $4.76, while analysts have projected $4.51 for fiscal year 2025.

Underwriting margins were largely unchanged relative to recent quarters, and top-line expansion slowed to low-single-digit growth in Q4. Management indicated expectations for improvement in future periods. The company has preserved a gross profit margin of 43.85% and delivered a return on equity of 21%, metrics that Cantor Fitzgerald highlighted in assessing the firm's financial strength. W.R. Berkley also posts a Piotroski Score of 9, a measure cited in the InvestingPro profile as signaling robust fundamentals.

Investment performance presented a mixed picture. Lower-than-expected catastrophe losses provided a cushion against weaker returns in an alternative investment sleeve, which produced a modest shortfall in net investment income. Cantor Fitzgerald noted that this shortfall did not materially affect core underwriting results. The insurer's market sensitivity remains low, with a beta of 0.39 compared with the broader market, and the company offers a 2.78% dividend yield after raising its payout for three consecutive years.

Cantor Fitzgerald commented that future growth appears "increasingly driven by greater confidence in products where pricing is viewed as rate adequate," describing that dynamic as "early soft-market growth." Valuation metrics cited in the InvestingPro analysis show a price-to-earnings ratio of 14.01 and a PEG ratio of 0.6, figures the platform flagged as indicating potentially attractive valuation relative to the company's growth prospects.

Additional brokerage reactions to the same set of results were less uniformly bullish. W.R. Berkley reported revenue of $3.72 billion for the quarter, exceeding consensus expectations of $3.19 billion, a 16.61% surprise. Despite the revenue beat, Jefferies reduced its price objective from $75.00 to $70.00 and retained a Hold stance. BofA Securities trimmed its target from $69.00 to $66.00 while maintaining a Neutral rating, noting the firm's earnings were slightly below its own forecast but in line with broader Street consensus.

Overall, the result produced a mix of analyst reactions. Cantor Fitzgerald's reiteration of an Overweight rating and its $76.00 target underscore one view that valuation and near-term product pricing dynamics support upside. Other brokerages' lowered targets and neutral or Hold ratings reflect more cautious assessments of near-term earnings and the margin outlook.


What the numbers show

  • Q4 diluted EPS: $1.13 (Cantor Fitzgerald estimate: $1.14).
  • Trailing twelve-month diluted EPS: $4.76.
  • Analysts' fiscal 2025 EPS forecast: $4.51.
  • Q4 revenue: $3.72 billion versus $3.19 billion expected (16.61% surprise).
  • Gross profit margin: 43.85%; return on equity: 21%.
  • Piotroski Score: 9; beta: 0.39; dividend yield: 2.78% with three consecutive annual raises.
  • Valuation: P/E 14.01; PEG 0.6.

Cantor Fitzgerald's view is that a return to stronger growth may be led by products where current pricing is deemed adequate, a factor the firm labeled as indicative of early stages of soft-market growth. The brokerage characterized the Q4 EPS outcome as effectively in-line, even though it missed its internal estimate by a penny.

Investors and analysts will likely weigh the firm's steady underwriting margins and strong profitability metrics against the mixed signals from investment income and the disparate reactions from sell-side firms. For those seeking deeper valuation and model-oriented analysis, InvestingPro offers a Pro Research Report on W.R. Berkley as part of its coverage universe.

Risks

  • Modest net investment income shortfall stemming from weakness in the alternative investment portfolio could pressure overall earnings - this primarily affects the financials and insurance sectors.
  • Slowing top-line growth, which moderated to low-single-digit levels in Q4, may constrain near-term earnings momentum for the insurance sector until pricing or volume improvements materialize.
  • Divergent analyst views - with Jefferies and BofA trimming price targets and maintaining Hold/Neutral ratings - indicate uncertainty among equity analysts about the sustainability of margins and earnings growth for the company.

More from Analyst Ratings

Palantir Gains After Lofty 2026 Guidance; Analysts Split on Outlook Feb 2, 2026 Freedom Capital Markets Starts Coverage of Nebius Group With Buy Rating, $108 Target Feb 2, 2026 Clear Street Starts Coverage on Caribou Biosciences with Buy Rating and $13 Target Feb 2, 2026 Goldman Keeps OLN Neutral at $22 as Olin Signals Rough Q1, Cost Cuts to Cushion Results Feb 2, 2026 Aletheia Capital Starts Coverage on Teradyne With Buy Rating, $400 Target Feb 2, 2026